Yushi Meng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yushi Meng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Chunyi Sun
Department of Gynecology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China
2 shared publicationsYang Liu
Department of Reproduction, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
2 shared publicationsChangjun Xu
Department of Reproductive Medicine, People’s Hospital of Yuxi City, Yuxi, China
1 shared publicationDongya Li
Department of Reproductive, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication- Honglin Zhou
Department of Gynecology, the Second Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication Jia Bie
Department of Reproductive, The Second Affiliated Hospital of Kunming Medical University, Kunming, China
1 shared publication
Latest Publications
- Open Access
- 8 October 2021
- Published by Springer Nature in BMC Women's Health
- Vol. 21 (1) , 1-6
Significance of the viral load of high-risk HPV in the diagnosis and prediction of cervical lesions: a retrospective study
Background: The significance of HPV viral load in the detection of cervical lesions is still controversial. This study analyzed the correlation between the high-risk HPV viral load and different cervical lesion degrees. Methods: This retrospective study included women positive for high-risk HPV DNA and screened for cervical lesions between 01/2015 and 06/2018. The high-risk HPV DNA load was measured by the second-generation Hybrid Capture technology and classified as low, moderate, and high. Colposcopy and biopsy were performed in all patients. The patients were grouped as normal, cervical intraepithelial neoplasia (CIN) grade 1, CIN grade 2, CIN grade 3, and cervical cancer. Multivariable logistic regression was performed to explore the association between high-risk HPV DNA load and cervical lesions. The odds ratios (ORs) represent the odds for increasing from low to high viral load. Results: Finally, 265 patients were grouped as normal (n = 125), CIN 1 (n = 51), CIN 2 (n = 23), CIN 3 (n = 46), and cervical cancer (n = 20). Among them, 139 (52.5%) had a low viral load, 90 (34.0) had a moderate viral load, and 36 (13.4%) had a high viral load. Taking the normal control group as a reference, a high viral load was an independent factor for CIN 1 (OR = 3.568, 95% CI: 1.164–10.941, P = 0.026), CIN 2 (OR = 6.939, 95% CI: 1.793–26.852, P = 0.005), CIN 3 (OR = 7.052, 95% CI: 2.304–21.586, P = 0.001), and cervical cancer (OR = 8.266, 95% CI: 2.120–32.233, P = 0.002). Conclusions: Among women who underwent cervical biopsy, higher high-risk HPV viral load in cervical lesions was associated with a higher risk of high-grade cervical lesions.
- 8 October 2021
- Published by Springer Nature in BMC Women's Health
- Vol. 21 (1) , 1-6
Open AccessSignificance of the viral load of high-risk HPV in the diagnosis and prediction of cervical lesions: a retrospective study
Background: The significance of HPV viral load in the detection of cervical lesions is still controversial. This study analyzed the correlation between the high-risk HPV viral load and different cervical lesion degrees. Methods: This retrospective study included women positive for high-risk HPV DNA and screened for cervical lesions between 01/2015 and 06/2018. The high-risk HPV DNA load was measured by the second-generation Hybrid Capture technology and classified as low, moderate, and high. Colposcopy and biopsy were performed in all patients. The patients were grouped as normal, cervical intraepithelial neoplasia (CIN) grade 1, CIN grade 2, CIN grade 3, and cervical cancer. Multivariable logistic regression was performed to explore the association between high-risk HPV DNA load and cervical lesions. The odds ratios (ORs) represent the odds for increasing from low to high viral load. Results: Finally, 265 patients were grouped as normal (n = 125), CIN 1 (n = 51), CIN 2 (n = 23), CIN 3 (n = 46), and cervical cancer (n = 20). Among them, 139 (52.5%) had a low viral load, 90 (34.0) had a moderate viral load, and 36 (13.4%) had a high viral load. Taking the normal control group as a reference, a high viral load was an independent factor for CIN 1 (OR = 3.568, 95% CI: 1.164–10.941, P = 0.026), CIN 2 (OR = 6.939, 95% CI: 1.793–26.852, P = 0.005), CIN 3 (OR = 7.052, 95% CI: 2.304–21.586, P = 0.001), and cervical cancer (OR = 8.266, 95% CI: 2.120–32.233, P = 0.002). Conclusions: Among women who underwent cervical biopsy, higher high-risk HPV viral load in cervical lesions was associated with a higher risk of high-grade cervical lesions.
- Open Access
- 3 December 2019
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 801
Menopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis
Background: Findings by epidemiologic studies on menopausal hormone replacement therapy (HRT) and the risk of ovarian cancer are inconsistent. This study aimed to assess the association of menopausal HRT with the risk of ovarian cancer by histological subtype. Methods: A literature search was performed in PubMed, Web of Science, and EmBase for relevant articles published from inception to August 2018. Pooled relative risk ratios (RRs) with 95% confidence intervals (CIs) were determined with a random-effects model. Results: Thirty-six studies involving 4, 229, 061 participants were included in this meta-analysis. The pooled RR of ovarian cancer was 1.29 (95%CI 1.19–1.40, I2 = 57.4%) for menopausal HRT. In subgroup analysis by study design, pooled RRs of ovarian cancer in cohort and case-control studies were 1.35 (95%CI 1.19–1.53) and 1.24 (95%CI 1.11–1.38), respectively. In subgroup analysis by continent, association of menopausal HRT with ovarian cancer was significant for North America (1.41 [1.23–1.61]), Europe (1.22 [1.12–1.34]), and Asia (1.76 [1.09–2.85]), but not Australia (0.96 [0.57–1.61]). Association differed across histological subtypes. Increased risk was only found for two common types, including serous (1.50 [1.35–1.68]) and endometrioid (1.48 [1.13–1.94]) tumors. Conclusion: This meta-analysis suggests that menopausal HRT may increase the risk of ovarian cancer, especially for serous and endometrioid tumors.
- 3 December 2019
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 801
Open AccessMenopausal Hormone Replacement Therapy and the Risk of Ovarian Cancer: A Meta-Analysis
Background: Findings by epidemiologic studies on menopausal hormone replacement therapy (HRT) and the risk of ovarian cancer are inconsistent. This study aimed to assess the association of menopausal HRT with the risk of ovarian cancer by histological subtype. Methods: A literature search was performed in PubMed, Web of Science, and EmBase for relevant articles published from inception to August 2018. Pooled relative risk ratios (RRs) with 95% confidence intervals (CIs) were determined with a random-effects model. Results: Thirty-six studies involving 4, 229, 061 participants were included in this meta-analysis. The pooled RR of ovarian cancer was 1.29 (95%CI 1.19–1.40, I2 = 57.4%) for menopausal HRT. In subgroup analysis by study design, pooled RRs of ovarian cancer in cohort and case-control studies were 1.35 (95%CI 1.19–1.53) and 1.24 (95%CI 1.11–1.38), respectively. In subgroup analysis by continent, association of menopausal HRT with ovarian cancer was significant for North America (1.41 [1.23–1.61]), Europe (1.22 [1.12–1.34]), and Asia (1.76 [1.09–2.85]), but not Australia (0.96 [0.57–1.61]). Association differed across histological subtypes. Increased risk was only found for two common types, including serous (1.50 [1.35–1.68]) and endometrioid (1.48 [1.13–1.94]) tumors. Conclusion: This meta-analysis suggests that menopausal HRT may increase the risk of ovarian cancer, especially for serous and endometrioid tumors.